Talk:Dendreon Corporation (DNDN)

From ValueWiki

Launch Chat Window 

NASD \ Healthcare \ Biotechnology

First Post

What do you think about this company? If you have general comments, add a reply to this section by clicking the [edit] link here ----->

ValueSpider 18:54, 27 November 2006 (PST)

Looking Good

Khartand, this article is looking pretty good. Nice work. Jonathan Stokes 13:27, 4 April 2007 (PDT)

FDA Approval

I had not heard of the company before last week when the advisory committee recommendation for FDA approval on May 15 hit the news and the stock price doubled. So I was a latecomer and bought at $14.25. The CEO has since sold 20 percent of his DNDN holdings, which seems like a rational thing to do, and not too scary for the rest of us.

Apparently, Dendreon’s treatment (Provenge) can give patients with end-stage prostate cancer another 4 months or so of reasonable living, unlike chemo, which can sometimes be horrible, I gather. The Provenge principle might also apply to other cancers. I attended a friend's funeral just last week. Breast cancer, and too young to die.

One analyst thought that the Provenge treatment, to gain that extra four months, might cost $60,000. Seems a lot, but then I remembered the Milton Berle joke -- Robber: Your money or your life! Milton: Wait a minute, I'm thinking about it.

Last week, another pharma stock (I forget the name) tried to play the "me too" game and threatened Provenge’s dominance, and the DNDN stock price. But apparently the Provenge technique, or technology, is different and Dendreon is well out in front of competitors.

So, on May 15, DNDN could spike again, or go poof. Should be fun. Bellbird1 14:21, 7 April 2007 (PDT)

I think most of the upside has been realized already. Well, the FDA still may decide against the panel recommendation and not approve Provenge, but it almost never act against a panel vote. So the stock might rise a bit more on FDA approval as that last bits of uncertainty is removed. However, I think the next big catalyst for the stock is how Provenge will actually perform in the market. Seems like expectation is lofty as some analyst are touting the drug as having billion dollar market potential, here's an example. It will be interesting if doctors, payors and patient will decide that the benefit of the vaccine os worth the cost. As I noted, the drug wasn't really proven effective at anything but prolonging survival.

--khartand 11:24, 9 April 2007 (PDT)

I sold DNDN at $22.40. I had not known when I bought the stock that Cramer had recommended shorting it. Ignorance is bliss.Bellbird1 04:29, 10 April 2007 (PDT)

Jim Cramer was wrong

Jim Cramer tries to set the record straight on why he told everyone to sell Dendreon last month. Backpedal, backpedal... Jonathan Stokes 12:13, 9 April 2007 (PDT)

Haha I admit that I was kind of in the bear camp too before. I didn't think the data was compelling enough for me to think that the FDA panel would overwhelmingly recommend approval of the drug. But looking at the market reaction and 4x / 5x pop in stock price after the FDA panel review, I think many other people were surprised too by the outcome of that meeting.

Disclaimer: I don't have any position in the stock. (I wish I did though)

--khartand 19:54, 9 April 2007 (PDT)

Thank God I was in the Sideline for this

Between the time of FDA Panel review recommendation and the dreaded "approvable" letter, I was tempted at times to buy, especially during some minor dips. Still trying to digest the events fully. This is one of the rare occasions where the FDA did not follow the recommendation of its review panel. But I guess one thing is clear, the FDA is still on the conservative mode when reviewing new drug applications. --khartand 09:34, 9 May 2007 (PDT)

Down 60% today...Ouch! Maybe Jim Cramer was right on his sell recommendation... Jonathan Stokes 09:51, 9 May 2007 (PDT)

Yeah... About Cramer, I think he recommended sell when the stock was around $4, so people who bought when he said sell still made profit. Let me double check on this though, but I would love to nit-pick on Cramer. On an unrelated note, I really want to know what happened behind the scenes. This case seemed to be an FDA internal politics soap opera. --khartand 10:39, 9 May 2007 (PDT)